GABPA

Across TCGA pan-cancer cohorts, GABPA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GABPA data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GABPA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GABPA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and SKCM are the cancer types where GABPA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.170	0.844	<.001	42	view →
BLCA	OS	Median	IV	0.018	0.600	<.001	12	view →
SKCM	DFS	Median	All	0.255	0.623	.001	12	view →
READ	DFS	Median	IV	0.082	0.619	.001	6	view →
UCEC	DFS	Median	All	1.000	0.891	.026	4	view →
STAD	OS	Median	All	0.111	0.538	.028	3	view →
COAD	OS	Median	All	0.318	0.586	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GABPA–OV (OS)

Open the OV breakdown →